Neuro-oncology
Overview
Neuro-oncology is a peer-reviewed journal dedicated to advancing the understanding and treatment of brain and central nervous system tumors. It publishes cutting-edge research on the molecular biology, genetics, pathology, imaging, and clinical aspects of neuro-oncology, providing a platform for interdisciplinary collaboration and dissemination of knowledge in this rapidly evolving field.
Details
Details
Abbr.
Neuro Oncol
Publisher
Oxford University Press
Start
1999
End
Continuing
Frequency
Twevle no. a year, 2010-
p-ISSN
1522-8517
e-ISSN
1523-5866
Country
United Kingdom
Language
English
Metrics
Metrics
h-index / Ranks: 1195
163
SJR / Ranks: 168
6348
CiteScore / Ranks: 268
22.50
JIF / Ranks: 208
15.9
Recent Articles
1.
Klassen D, Mok S, Hwang J, Blount S, Williams K, Fong B, et al.
Neuro Oncol
. 2025 Mar;
PMID: 40084913
Background: Readmission following endoscopic endonasal transsphenoidal surgery (EETS) for pituitary neuroendocrine tumor (PitNET) and other sellar pathology is most commonly due to delayed hyponatremia. Studies suggest post-operative fluid restriction (FR)...
2.
Li F, Bondra K, Wang H, Kurmashev D, Mukherjee B, Kanji S, et al.
Neuro Oncol
. 2025 Mar;
PMID: 40083135
Background: MAPK pathway inhibitors (MAPKi) have shown significant efficacy in treating childhood BRAF-activated brain tumors. For tumors harboring BRAFV600E mutations, the drugs are rarely curative, and patients can become refractory...
3.
Mateos M, Ajuyah P, Fuentes-Bolanos N, El-Kamand S, Barahona P, Altekoester A, et al.
Neuro Oncol
. 2025 Mar;
PMID: 40072012
Background: Factors that drive the development of diffuse midline gliomas (DMG) are unknown. Our study aimed to determine the prevalence of pathogenic/likely pathogenic (P/LP) germline variants in pediatric patients with...
4.
Gust J, Cole B, Ronsley R, Wilson A, Seidel K, Wendler J, et al.
Neuro Oncol
. 2025 Mar;
PMID: 40070357
Background: Relapsed/refractory pediatric CNS tumors have a poor prognosis. EGFR is commonly overexpressed, but EGFRvIII mutations are uncommon. To target these tumors, we used chimeric antigen receptor (CAR) T cells...
5.
6.
7.
Jalali R, Ghosh S, Chatterjee A, Goswami S, Shah N, Dutta D, et al.
Neuro Oncol
. 2025 Mar;
PMID: 40056158
Background: The evolving treatment paradigm in children and adolescents with craniopharyngioma (CP) aims at minimizing late functional sequelae. Advanced radiotherapeutic techniques offer theoretical advantages of preserving neurological functions, however, clinical...
8.
Hernandez-Verdin I, Kirasic E, Mokhtari K, Barillot N, Rincon de la Rosa L, Sourdeau E, et al.
Neuro Oncol
. 2025 Mar;
PMID: 40048707
Background: Primary central nervous system lymphoma (PCNSL) treatment relies on a high-dose methotrexate based chemotherapy (HD-MTX-based CT) regimen; however, whether there is a specific microbiota composition association with treatment response...
9.
Garcia Barbera F, Picech F, Cecenarro L, Mezger G, Faure E, Zlocowski N, et al.
Neuro Oncol
. 2025 Mar;
PMID: 40045561
Background: In somatotroph tumors, over 50% of patients do not respond satisfactorily to the octreotide (OCT) treatment. Stimulation of SSTR2 with OCT triggers anti-proliferative signaling pathways mediated by the phosphatase...
10.
Delaidelli A, Burwag F, Ben-Neriah S, Suk Y, Shyp T, Kosteniuk S, et al.
Neuro Oncol
. 2025 Mar;
PMID: 40040502
Background: While international consensus and the 2021 WHO classification recognize multiple molecular medulloblastoma subgroups, these are difficult to identify in clinical practice utilizing routine approaches. As a result, biology-driven risk...